Alloy Therapeutics Files for IPO Following $40M Series E Round at $1B Valuation
Alloy Therapeutics
Drug Discovery and Development Service Provider
▲May 14-15Shanghai BiopharmaceuticalsInnovators SummitScan to Register
Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
PharmaCircleMonitoring shows: Alloy Therapeutics disclosed on April 15 that it had completed a US$40 million Series E financing round, with a valuation of US$1 billion.
Under the leadership of founder and CEO Errik B. Anderson,ATX-Gx™With the fully human antibody transgenic mouse platform as the cornerstone, we simultaneously cultivate in-depth expertise.AntiClastic™ ASODiverse technology platforms such as antisense nucleic acids, TCR mimetics, gene drugs, and next-generation cell therapies form a comprehensive R&D matrix covering various modalities including antibodies, bispecific antibodies (dual-antibodies), ADCs, radioligand therapies, and iPSC-derived iCAR-T/iCAR-NK, with a core focus on high-demand areas like oncology, fibrosis, central nervous system diseases, and rare genetic disorders.。
In terms of R&D progress, the company is accelerating the clinical application of the Mediar project targeting complex fibrosis by 2026, and multiple antibody and TCRm candidates for refractory tumors are steadily advancing in preclinical validation.
AntiClastic™ ASOThe platform, with dual advantages of optimized nucleic acid spatial conformation and sequence design, significantly enhances drug efficacy, tissue targeting, and safety. Multiple ASO molecules targeting neurodegenerative and hereditary diseases have entered the candidate optimization stage.
In terms of team structure, the company has gathered top talents across fields. President & CSO Piotr Bobrowicz oversees the overall scientific strategy, Richard Shimkets heads the Antibody-Driven Business Unit, Christian Cobaugh will serve as CEO of the Gene Medicine Department in 2025, comprehensively leading the expansion of antisense nucleotides and gene medicines, and Heather Schwoebel serves as Chief Business Officer, leading global BD and strategic cooperation.
Dongxing Zha Serves as CTO, Focusing on TCR Discovery and Engineering Technology, forming a complete professional梯队 from basic research, technology development to clinical transformation.
BD Cooperation LevelAlloy Therapeutics has built a network of over 200 global partners, with platform licensing, multi-target alliances, and joint ventures as its core model.
In recent years, major BD deals have been intensively implemented.: Just recently, on April 6, 2026, andBiogenAchieve Multi-Target Collaboration, AuthorizationAntiClastic™ ASOPlatform develops drugs for central nervous system diseases; in March,AbbVieBuild a new antibody platform together to tackle difficult drug targets;
2025 Year withSanofiSign agreements with a total value exceeding $400 million, focusing on CNS gene therapies;
2024 Year withTakedaCollaborative Development of iPSC-Derived iCAR-T/iCAR-NK Cell Therapies;
In early 2026, successively withTahoe TherapeuticsEstablish a joint venture to develop first-in-class ADCs, withSwiss Rockets GroupJoin hands to advance tumor radioligand therapy, while continuing to collaborate withPfizerDeepening Antibody Discovery Platform Collaboration with Pharmaceutical Companies。
References:
PharmaCircle Data;
Moxie Pharma pharma.bcpmdata.com (formerly Pharma Data Cloud);
http://www.marketscreener.com；
https://www.businesswire.com；
www1.hkexnews.hk/；
https://alloytx.com/；
https://www.biotechtv.com/post/alloy-therapeutics-april-7-2026；
https://alloytx.com/alloy-biogen-aso-platform-collaboration/；
; etc.
